Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

被引：0

作者：

Kersten, Marie Jose ^{[1
,2
]}

Dreyling, Martin ^{[3
]}

Linton, Kim M. ^{[4
,5
]}

Chitu, Dana ^{[6
]}

Tonino, Sanne ^{[7
]}

Kap, Marcel ^{[8
]}

Liu, Roberto D. ^{[9
]}

Chamuleau, Martine E. D. ^{[10
]}

Visser, Hein P. J. ^{[11
]}

De Jongh, Eva ^{[12
]}

Marijt, Erik Waf ^{[13
]}

Leijs, Maria B. L. ^{[14
,15
]}

Bilgin, Yavuz M. ^{[16
]}

Duerig, Jan ^{[17
]}

McKay, Pamela ^{[18
]}

Snijders, Tjeerd J. F. ^{[19
]}

Pettitt, Andrew ^{[20
,21
]}

Minnema, Monique C. ^{[22
]}

Prange-Krex, Gabriele ^{[23
]}

Cuijpers, Maria ^{[24
]}

Boehmer, Lara H. ^{[25
]}

Tick, Lidwine W. ^{[26
]}

Florschuetz, Axel ^{[27
]}

Silbermann, Matthijs ^{[28
]}

Fijnheer, Rob ^{[29
]}

Beeker, Aart ^{[30
]}

Tolboom, Nelleke ^{[31
]}

Mitea, Cristina ^{[32
]}

Arens, Anne I. J. ^{[33
]}

Zwezerijnen, Gerben J. C. ^{[34
]}

Klapper, Wolfram ^{[35
]}

Coupland, Sarah E. ^{[36
]}

de Jong, Daphne ^{[37
]}

Doorduijn, Jeanette K. ^{[38
]}

Zijlstra, Josee M. ^{[10
]}

机构：

[1] Amsterdam Univ Med Ctr, Locat Univ Amsterdam, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Amsterdam, Netherlands

[3] Klinikum Univ Muenchen, Dept Med 3, Campus Grosshadern, Munich, Germany

[4] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[5] Christie Hosp, Manchester, Lancs, England

[6] Erasmus MC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[7] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[8] ErasmusMC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[9] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[10] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[11] Med Ctr Alkmaar, Hematol, Alkmaar, Netherlands

[12] Albert Schweitzer Hosp, Dept Hematol, Dordrecht, Netherlands

[13] Leiden Univ Hosp, Hematol, Leiden, Netherlands

[14] Maasstad Ziekenhuis, Rotterdam, Netherlands

[15] Maasstad Ziekenhuiis, Rotterdam, Netherlands

[16] Admiraal de Ruijter Hosp, Dept Internal Med, Goes, Netherlands

[17] Essen Univ Hosp, Dept Hematol, Essen, Germany

[18] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[19] Med Spectrum Twente, Enschede, Netherlands

[20] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, Merseyside, England

[21] Univ Liverpool, Liverpool, Merseyside, England

[22] Univ Med Ctr, Dept Hematol, Utrecht, Netherlands

[23] Gemeinschaftspraxis Mohm Prange Krex, Dresden, Germany

[24] Viecuri Med Ctr, Venlo, Netherlands

[25] Haga Teaching Hosp, Dept Hematol, The Hague, Netherlands

[26] Maxima Med Ctr, Veldhoven, Netherlands

[27] Klinikum Dessau, Hematol, Dessau, Germany

[28] Ter Gooi Hosp, Hilversum, Netherlands

[29] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands

[30] Sparne Ziekenhuis, Hoofddorp, Netherlands

[31] Univ Med Ctr Utrecht, Nucl Med, Utrecht, Netherlands

[32] Maastricht Univ, Med Ctr, Nucl Med, Maastricht, Netherlands

[33] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[34] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC,Locat VUmc, Amsterdam, Netherlands

[35] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

[36] Univ Liverpool, Pathol, Liverpool, Merseyside, England

[37] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands

[38] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-156085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2283 / 2285

页数：3

共 50 条

[1] HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Stevens, Wendy B. C.
Bakunina, Katerina
Cuijpers, Marloes
Chamuleau, Martine
Beeker, Aart
Fijnheer, Rob
Hebart, Holger
Visser, Hein P. J.
Doorduijn, Jeanette K.
Linton, Kim
Dreyling, Martin
de Jong, Daphne
Kersten, Marie Jose
HEMASPHERE, 2020, 4 (01):
[2] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Della Cioppa, P.
Lucania, A.
Esposito, M.
Improta, S.
Mastrullo, L.
HAEMATOLOGICA, 2015, 100 : 151 - 151
[3] A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
Cheson, Bruce D.
Crawford, Jeanette
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 528 - 533
[4] A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.
Paikaray, Susanta Kumar
Gogia, Ajay
Kumar, Lalit
Sharma, Atul
Biswas, Ahitagni
Sharma, Mehar C.
Thulker, Sanjay
Kumar, Rakesh
Vishnubhatla, Sreenivas
Mallick, Saumyaranjan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M Wang
N Fowler
N Wagner-Bartak
L Feng
J Romaguera
S S Neelapu
F Hagemeister
M Fanale
Y Oki
B Pro
J Shah
S Thomas
A Younes
C Hosing
L Zhang
K J Newberry
M Desai
N Cheng
M Badillo
M Bejarano
Y Chen
K H Young
R Champlin
L Kwak
L Fayad
Leukemia, 2013, 27 : 1902 - 1909
[6] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Wang, M.
Fowler, N.
Wagner-Bartak, N.
Feng, L.
Romaguera, J.
Neelapu, S. S.
Hagemeister, F.
Fanale, M.
Oki, Y.
Pro, B.
Shah, J.
Thomas, S.
Younes, A.
Hosing, C.
Zhang, L.
Newberry, K. J.
Desai, M.
Cheng, N.
Badillo, M.
Bejarano, M.
Chen, Y.
Young, K. H.
Champlin, R.
Kwak, L.
Fayad, L.
LEUKEMIA, 2013, 27 (09) : 1902 - 1909
[7] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
Burke, J. M.
Andorsky, D. J.
Yacoub, A.
Melear, J.
Coleman, M.
Kolibaba, K.
Brooks, H.
Bitran, J.
Fanning, S.
Lansigan, F.
Ricker, J. L.
Foon, K.
Llorente, M.
Li, J.
Sharman, J.
HAEMATOLOGICA, 2017, 102 : 249 - 250
[8] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Falchi, Lorenzo
Abrisqueta, Pau
Nijland, Marcel
Leppa, Sirpa
Hutchings, Martin
Holte, Harald
Merryman, Reid W.
Lugtenburg, Pieternella
de Vos, Sven
Cheah, Chan Y.
Christensen, Jacob Haaber
Arcaini, Luca
Drott, Kristina
Hellstrom, Mats
Leslie, Lori A.
Vitolo, Umberto
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Belada, David
BLOOD, 2022, 140 : 1464 - 1466
[9] A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma
Paikaray, Sushant Kumar
Gogia, Ajay
Kumar, Lalit
Sharma, Atul
Biswas, Ahit Agni
Vishnubhatla, Sreeniwas
Mallick, Soumya
INDIAN JOURNAL OF CANCER, 2023, 60 (04) : 501 - 504
[10] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
Fowler, Nathan
Kahl, Brad S.
Lee, Peter
Matous, Jeffrey V.
Cashen, Amanda F.
Jacobs, Samuel A.
Letzer, Jeffrey
Amin, Bipinkumar
Williams, Michael E.
Smith, Sonali
Saleh, Alfred
Rosen, Peter
Shi, Hongliang
Parasuraman, Sudha
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395

← 1 2 3 4 5 →